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Objective: In this randomized clinical trial ginger efficacy for prevention of
antiretroviral-induced nausea and vomiting (N/V) was investigated.
Methods: From July 2011 until the end of June 2013, 102 HIV positive patients
attending the HIV clinic of Imam Khomeini Hospital participated in the study.
In a double blinded manner, participants randomly received either 500 mg
ginger or placebo two times per day, 30 min before each dose of antiretroviral
regimen for 14 days. The severity of nausea was assessed based on the visual
analogue scale. The number of vomiting episodes were also recorded during
the study period.
Results: A total of 46 (90.2%) and 29 (56.4%) of the patients in placebo and
ginger groups experienced some degree of nausea during the first 2 weeks
of antiretroviral therapy (ART), respectively (p = 0.001). Frequency of mild,
moderate and severe nausea were significantly lower in the ginger than pla-
cebo group (p = 0. 001). Also, 24 (47.1%) and 5 (9.8%) of the patients in the
placebo and ginger groups reported at least one episode of vomiting during
their time on ART, respectively (p = 0.01).
Conclusion: Ginger was effective in ameliorating of antiretroviral-induced N/V.
Keywords: antiretroviral, ginger, nausea, vomiting
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1. Introduction
Nausea and vomiting (N/V) are common side effects of antiretroviral therapy
(ART) and usually occur early during the treatment course of HIV. Although these
gastrointestinal adverse effects are usually self-limiting and disappear with continu-
ing ART, they can affect patients’ ART adherence [1,2]. Approximately 42 -- 57%
and 28 -- 32% of patients receiving ART experience some degree of N/V, respec-
tively [3]. Nucleoside reverse transcriptase inhibitors (especially zidovudine and
didanosine), protease inhibitors (PIs) (including indinavir) and non-nucleoside
reverse transcriptase inhibitors (NNRTIs) can induce N/V [1,2]. More than two-
third of people who received initial regimen from older antiretroviral drugs experi-
enced significant adverse effects, including N/V [4]. However, with newer classes of
ART including entry inhibitors, these complaints are less common [5].
In the severe forms of ART-induced N/V, discounting offending drug or switching
to alternative drug may be considered. In the mild-to-moderate N/V, supportive and
pharmacological approaches may be effective. Antiemetic agents including those with
a combined dopamine antagonist, 5-hydroxytryptamine (5-HT) 3 antagonist and
5-HT4 agonist activity (metoclopramide), serotonin 5-HT3 receptor antagonists
(ondansetron and granisetron), phenothiazines (promethazine and chlorpromazine),
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antihistamines, anticholinergics, butyrophenones, cannabi-
noids (dronabinol) and corticosteroids are used as antiemetic
agents [3,6]. Significant adverse effects, drug--drug interactions
and the cost of these medications are important issues. An effec-
tive natural product with limited drug interactions, defined
safety profile and low cost is promising.
Powdered rhizome of ginger (Zingiber officinale) as a botani-
cal remedy is used for alleviating N/V in several conditions [7,8].
Antioxidant, antimicrobial, antifungal, antineoplastic, antith-
rombotic, antidiabetic, antihyperlipidemic and antihyperten-
sive effects have been reported for ginger [7,8]. Adverse effects
related to ginger including heartburn, diarrhea and mouth
irritation are mild and uncommon [9,10]. However, ginger has
showed inhibitory effect on CYP enzyme activity and this
should be considered when administered concomitantly with
PIs specially ritronavir [11]. The main active constituents of
ginger are gingerol shogaol [12]. The exact antiemetic mecha-
nism of gingerol is unknown. Inhibition of cholinergic
M3 and serotonergic 5-HT3 and 5-HT4 receptors, dopamine,
substance P and NK1 receptors at the peripheral and central
levels are the proposed mechanisms [12-15]. Ginger showed
positive effects in controlling pregnancy-induced N/V [16,17].
It has also showed beneficial effects in the prevention and treat-
ment of postoperative nausea and vomiting (PONV) and
chemotherapy-induced nausea and vomiting (CINV) [7,18-20].
Based on the available evidence, it seems that ginger may be
an effective, safe and inexpensive option for prevention of
ART-induced N/V. In this randomized clinical trial for the first
time, the efficacy of ginger for the prevention of ART-induced
N/V was evaluated.
2. Method
2.1 Type of study and setting
This double-blind, placebo-controlled, randomized clinical
trial was conducted in the HIV clinic of Imam Khomeini
Hospital, a referral teaching hospital affiliated to Tehran
University of Medical Sciences, Tehran, Iran, from July
2011 up to the end of June 2013. This clinic is responsible
to provide free-charge patient’s care (diagnostic, treatment
and consultation) for the refereed HIV-positive individuals
from all areas of Tehran province. Up to starting time of
the study, about 1200 HIV-positive individuals registered in
this clinic. Management of the HIV-positive individuals in
the clinic is based on the local Iranian HIV/AIDS guideline.
According to this guideline, efavirenz plus lamivudine and
zidovudine is the first-line ART regimen. Lopinavir/ritonavir
and didanosine are alternative medications.
The Institutional Review Board and the Medical Ethics
Committee of the hospital approved the study. The study is
in accordance with the Helsinki Declaration. Informed con-
sent was obtained from all patients or their family members.
The trial was registered in the Iranian Registry of Clinical
Trial with ID number IRCT201305283449N12.
2.2 Patients
Sample size of the study was calculated based on the data of
previous study (3), a = 0.05 and 80% power (1-b = 0.8).
During the study period, 176 HIV-positive patients were
eligible for initiating ART. Following initial interview, only
137 adult patients (18 -- 65 years old) agreed to participate
in the study and signed the consent form. In the second phase
of interview, patients with underlying gastrointestinal disor-
ders (current and history of peptic ulcers, dyspepsia, N/V,
using antiemetic and antiacid products), noncompliance,
positive history for ginger hypersensitivity and concomitant
anticoagulant therapy were excluded. A total of 115 patients
were initially included, with 102 patients completing the
study (Figure 1). Following patients’ medical records review,
the patients’ demographic and clinical data were recorded.
The included patients were assigned to either the ginger or
placebo group based on simple randomization. Capsules of
ginger were provided from the GOLDAROO pharmaceutical
company, Isfahan, Iran. Ginger capsules are available as a
herbal product in the Iranian pharmaceutical market and
each capsule contained 250 mg standard powdered rhizome
of ginger. Periodical analysis and quality control of the prod-
uct is carried out by the company under supervision of the
standard Drug and Food Control Laboratory affiliated to
the Ministry of Health, Tehran, Iran. Placebo capsules filled
with starch were the same shape and provided in the same
packaging to the ginger capsule. They were manufactured by
the same pharmaceutical company.
Each included patient referred to pharmacy department of
the HIV/AIDS clinic was divided by the simple randomization
method into the ginger or placebo group by a pharmacy tech-
nician. The main researcher (clinical pharmacist) and patients
were blinded regarding the type of capsules. Participants
received either two capsules of ginger (500 mg) or placebo,
two times per day, which was taken 30 min before each dose
of ART for 14 days. All included patients were educated
regarding gastrointestinal adverse effects of ART and asked to
avoid any medication for controlling gastrointestinal problems
including N/V. Any patient who needed antiemetics, antia-
cids, nonadherent with ART regimens or cessation of ART
for controlling ART-induced gastrointestinal problems was
withdrawn from the study.
An expert clinical pharmacist in the field of infectious
diseases was responsible for education of the patients regard-
ing gastrointestinal adverse effects of ART, N/V assessment
and patient follow-up by phone and at visit times. All patients
were advised regarding their use of ART regimen and were
asked not to change their meal regimens during the study
period. Severity of nausea was assessed based on the visual
analogue scale (VAS); an instrument for subjective character-
istics or attitudes that cannot be directly measured. A standard
VAS was used that point 0 equals to the absence of nausea and
point 10 was taken into account as the most severe condition
of nausea. Scores £ 3, 4 -- 7 and > 7 were considered as mild,
F. Dabaghzadeh et al.
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moderate and severe nausea, respectively. The validity of the
VAS was evaluated by an expert clinical pharmacist. Internal
consistency reliability was evaluated by the finding the
Cronbach’s a-coefficient for all items on a 20 randomly
selected non-HIV-infected patients involved with N/V.
Test--retest reliability was assessed by finding the intra-cluster
correlation on the same sample after a week. According to the
findings, content modification of the VAS was applied and its
finalized format was employed. Initially, patients were edu-
cated regarding this scale and a copy of the scale was given
to each patient. The patients were monitored daily via phone
calls during which they were asked about their adherence to
treatment regimens and gastrointestinal adverse effects
(including N/V) during the first 14 days of therapy by a clin-
ical pharmacist. At two clinic visits at the beginning and the
end of follow-up as well as during daily phone calls, patients
were asked to report any episode of gastrointestinal adverse
reaction including N/V. The clinical pharmacist asked
patients who experienced nausea to determine the severity of
each episode of nausea based on the in-hand VAS scale.
2.3 Statistical analyses
The statistical package of social science version 11.5 was used
for all analyses. Means ± standard deviations (SDs) were cal-
culated for continuous variables and percentage for categorical
variables. All data were examined for normal distribution by
the Kolmogorov--Smirnov test. The c2 (or Fisher’s exact
test) was used to compare categorical demographic and clini-
cal data of patients. The Mann--Whitney U test was used to
compare non-normally distributed continuous variables. We
considered p < 0.05 as statistically significant.
3. Results
A total of 102 patients completed the study. Among these,
70 (68.6%) and 32 (31.4%) were male and female, respec-
tively. Mean ± SD age of the cohort was 35.89 ± 9.19 years.
NNRTIs-based regimen (efavirenz + lamivudine + zidovu-
dine) was the most common (97.0%) ART protocol. The
most frequent opportunistic infection in our patients was
candidiasis (9.80%). The most common (76.99%) indication
for starting ART in the subjects was CD4 < 350 cells/ml. The
major route of HIV transmission was intravenous drug use
(59.80%). Demographic characteristics and laboratory data
of the patients are shown in Tables 1 and 2. There was no
statistically significant difference between the ginger and con-
trol groups regarding baseline characteristics and laboratory
data (p > 0.05).
A total of 46 (90.2%) and 29 (56.9%) patients in the
placebo and ginger groups experienced some degree of nausea
during the first two weeks of ART, respectively (p = 0.001)
(Table 3). In total, 273 and 175 episodes of nausea were
recorded in the placebo and ginger groups, respectively
(Table 4). Frequency of mild, moderate and severe episodes
of nausea was significantly lower in the ginger group than in
the placebo group (p = 0.02, 0.04 and 0.001, respectively)
(Table 4). Also, 24 (47.1%) and 5 (9.8%) patients in the
placebo and ginger groups reported at least one episode of
vomiting, respectively (p = 0.01) (Table 5).
Assessment for eligibility (115 patients)
Allocated to ginger 500 mg b.i.d. (59)
Excluded (n = 8): 4 patients due to
non-adherence, 4 patients due to
loss of follow-up
Analyzed (n = 51)
Allocation to placebo (56)
Excluded (n = 5): 3 patients due to
non-adherence, 2 patients due to
loss of follow-up
Analyzed (n = 51)
Figure 1. Consort flowchart of the study.
b.i.d.:Two times a day.
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4. Discussion
Gastrointestinal complications including N/V are common
complaints of patients following initiating of ART regimens.
Most antiretroviral drugs cause transient N/V at the
beginning of therapy course. These adverse effects can result
in discontinuation of ART and patient nonadherence [1-3].
Mild N/V is usually self-limiting, but for moderate-to-severe
cases, antiemetic medications may be helpful. Dopamine
and serotonin antagonists, phenothiazines, antihistamines,
Table 1. The demographic characteristics of the patients.
Characteristics Ginger group
(51 patients)
Placebo group
(51 patients)
*p value
Number (%) or
mean ± SD
Number (%) or
mean ± SD
Sex Male 36 (70.58) 34 (66.66) 0.41
Female 15 (29.42) 17 (33.34)
Age 36.82 ± 9.29 34.7 ± 9.03 0.40
Time interval from HIV infection to reaching
AIDS stage (months)
18.22 ± 21.13 15.95 ± 11.34 0.22
Education Illiterate 4 (7.84) 3 (5.88) 0.11
Elementary 3 (5.88) 6 (11.76)
Guidance school 16 (31.37) 14 (27.45)
High school 22 (43.13) 25 (49.01)
More than diploma 6 (11.76) 3 (5.88)
Transmission routes IV drug injection 32 (62.74) 29 (56.86) 0.56
Sexual contact 11 (21.56) 10 (19.60)
Both IV drug injection and
sexual contact
4 (7.84) 8 (15.68)
Unknown 2 (3.92) 2 (3.92)
Blood product transfusion 2 (3.92) 2 (3.92)
Opportunistic infections TB 2 (3.92) 1 (1.96) 0.11
CMV 1 (1.96) 2 (3.92)
Candidiasis 3 (5.88) 2 (3.92)
Zoster 2 (3.92) 0 (0.0%)
Candidiasis 3 (3.58) 1 (1.96)
None 40 (78.43) 45 (88.23)
Concomitant diseases Diabetes 2 (3.92) 1 (1.96) 0.87
Depression 3 (5.88) 4 (7.84)
HCV 10 (19.60) 8 (15.68)
HBV and HCV 6 (11.76) 4 (7.84)
None 30 (58.82) 34 (66.66)
Stage of HIV infection A 31 (60.78) 36 (70.58) 0.32
B 13 (25.49) 8 (15.68)
C 7 (13.72) 7 (13.72)
Concomitant medications Cotrimaxazole 23 (45.09) 25 (49.01) 0.22
Gancyclovir 2 (3.92) 1 (1.96)
Benzodiazepine 4 (7.84) 2 (3.92)
SSRI 6 (11.76) 8 (15.68)
Fluconazole 4 (7.84) 4 (7.84)
INH 5 (9.80) 5 (9.80)
Anti-TB regimen
(INH, RIF, PYZ, ETM + Vit B6)
1 (1.96) 1 (1.96)
Acyclovir 3 (5.88) 1 (1.96)
Insulin 3 (5.88) 4 (7.84)
ART regimens Efavirenz + lamivudine +
zidovudine
42 (82.35) 44 (86.27) 0.10
Lopinavir/ritonavir +
lamivudine + zidovudine
7 (13.72) 6 (11.76)
Lamivudine + zidovudine + didanosine 2 (3.92) 1 (1.96)
*c2 or Fisher’s exact test.
ART: Antiretroviral therapy; B6: Vitamin B6; ETM: Ethambutol; HBV: Hepatitis B Virus; HCV: Hepatitis C virus; INH: Isoniazid; i.v.: Intravenous; NS: Not significant;
PYZ: Pyrazinamide; RIF: Rifampin; SSRI: Selective serotonin reuptake inhibitor; TB: Tuberculosis.
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Table 2. Patients’ laboratory data.
Variable (mean ± SD) Ginger group (51 patients) Placebo group (51 patients) *p value
WBC 4920.23 ± 1003.22 5661.23 ± 1994.8 0.11
CD4 count 238.23 ± 100.67 198.67 ± 150.99 0.45
Hemoglobin 11.22 ± 2.49 10.68 ± 1.84 0.89
Hematocrit 34.11 ± 4.67 33.99 ± 5.84 0.65
Platelets 195317.44 ± 104829.60 206441.52 ± 173125.22 0.54
Urea 22.00 ± 7.64 25.00 ± 10.19 0.44
Creatinine 1.05 ± 1.39 0.96 ± 0.21 0.23
ALT 58.91 ± 23.81 67.31 ± 24.14 0.45
AST 50.74 ± 67.16 56.86 ± 11.00 0.76
ALP 373.09 ± 42.45 287.18 ± 26.14 0.54
ESR 22.13 ± 9.11 25.31 ± 11.40 0.55
Cholesterol 129.32 ± 30.13 150.06 ± 31.50 0.09
Triglyceride 141.89 ± 43.20 182.11 ± 58.26 0.33
HDL 36.16 ± 12.10 30.11 ± 9.50 0.54
LDL 89.10 ± 23.10 96.11 ± 27.01 0.45
FBS 112.48 ± 24.49 122.60 ± 68.26 0.77
*Two tailed t test.
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ESR: Erythrocyte sedimentation rate; FBS: Fasting blood sugar;
HDL: High-density lipoprotein; LDL: Low-density lipoprotein; SD: Standard deviation; WBC: White blood cell.
Table 3. Number (%) of patients with and without nausea.
Treatment group Without
nausea, n (%)
With mild
nausea, n (%)
With moderate
nausea, n (%)
With severe
nausea, n (%)
Total patients with
nausea, n (%)
Ginger 22 (43.1) 9 (17.6) 16 (31.4) 4 (7.9) 29 (56.9)
Placebo 5 (9.8) 14 (27.4) 20 (39.2) 12 (23.6) 46 (90.2)
p* Value 0.001 0.02 0.04 0.001 < 0.001
*c2 test.
%: Percent of patients; n: Number of patients.
Table 4. Frequencies of nausea episodes and different intensities during first two weeks of ART.
Treatment group Mild nausea,
n (%)
Moderate nausea,
n (%)
Severe nausea,
n (%)
Total frequency,
n (%)
Ginger 63 (36.0) 84 (48.0) 28 (16.0) 175 (100)
Placebo 98 (35.9) 112 (41.0) 63 (23.1) 273 (100)
p Value < 0.001
*c2 test.
%: Percent of patients; ART: Antiretroviral therapy; n: Number of patients.
Table 5. Number (%) of patients with and without vomiting.
Treatment
group
Patients without
vomiting, n (%)
Patients with
one episode of
vomiting, n (%)
Patients with two
episodes of
vomiting, n (%)
Patients with 3 -- 6
episodes of
vomiting, n (%)
Patients with
more than six
episodes of
vomiting, n (%)
Total patients
with vomiting,
n (%)
Ginger 46 (90.2) 2 (3.9) 2 (3.9) 1 (2) 0 (0) 5 (9.8)
Placebo 27 (52.9) 12 (23.5) 5 (9.8) 4 (7.8) 3 (6) 24 (47.1)
p* Value 0.01 0.006 0.04 0.03 0.02 < 0.001
*c2 test.
%: Percent of patients; n: Number of patients.
Ginger for prevention of antiretroviral-induced nausea and vomiting
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anticholinergics, butyrophenones, cannabinoids and cortico-
steroids are usually recommended as antiemetic medications.
Adverse effects, drug interactions and cost are challenging
issues regarding antiemetic administration for the manage-
ment of ART-induced N/V [3]. A drug with favorable safety
profile, no significant drug interaction and low cost can be
considered as a desirable option for this purpose (indication).
Ginger is an ancient medicinal plant that has been used as an
antiemetic. Ginger has not shown any significant drug inter-
actions or side effects. It is inexpensive and is available around
the world [8,19,20].
Effects of ginger on the prevention of pregnancy-induced
N/V, PONV and CINV have been evaluated in the previous
studies, but this is the first time that preventive effects of ginger
against ART-induced N/V are examined. Ginger significantly
reduced the incidence of ART-induced N/V in the current
study. Our cohort also received a number medications (e.g.,
cotrimaxazole, fluconazole, benzodiazepines, selective seroto-
nin reuptake inhibitors, isoniazid, rifampin, pyrazinamide)
for either prophylaxis of opportunistic infections or manage-
ment of their comorbidities (such as depression and tuberculo-
sis) that may aggravate gastrointestinal adverse reactions of
ART. However, the number of patients given these agents
was comparable between placebo and ginger groups. This
was also true for medications with potential therapeutic effects
against N/V such as pyridoxine (vitamin B6).
Three independent study groups have investigated the
effect of ginger on prevention of CINV [20-22]. The results of
Sontakke et al. study showed that ginger is as effective as
metoclopramide in reducing CINV. In that study, partici-
pants randomly received three regimens. First regimen was
two capsules of ginger orally (each capsule contained
250 mg powdered ginger) and 2 ml of normal saline intrave-
nously (i.v.) 20 min before chemotherapy and then the dose
of ginger was repeated 6 h after chemotherapy. Second
regimen included two capsules of lactulose orally and meto-
clopramide (20 mg) i.v. given to patients 20 min before
chemotherapy and then they received two capsules of meto-
clopramide (5 mg) 6 h after chemotherapy. Third regimen
was two capsules of lactulose orally and ondansetron (4 mg)
i.v. 20 min before chemotherapy and then the patients
received two capsules of ondansetron (4 mg) 6 h after
chemotherapy [20].
Pillai et al. demonstrated that powdered ginger is as effec-
tive as add-on therapy to antiemetic medications for reducing
CINV in children and young adults. Participants with body
weight between 20 and 40 kg received 1 g/day ginger (6 capsu-
les of 167 mg ginger) or matching placebo from day 1 to day
3 of chemotherapy. Patients with body weight between
40 and 60 kg took 2 g/day ginger (5 capsules of 400 mg
ginger) or matching placebo from day 1 to day 3 of chemo-
therapy [21]. In another study, ginger at doses of 0.5 and 1 g
per day significantly reduced CIN as add-on to standard anti-
emetic regimens. Patients randomly assigned into four groups
and received placebo, 0.5, 1 or 1.5 g ginger per day. Three
capsules (ginger extract or placebo) were given twice daily
for 6 days, started 3 days before chemotherapy [22].
Bone et al. and Nanthakomon and Pongrojpaw evaluated
the effect of ginger on the prevention of PONV [23,24]. In the
Bone et al. study, ginger significantly reduced PONV and
additional antiemetic medications were needed. The
antiemetic effect of ginger was similar to metoclopramide.
Patients were randomly divided into three groups. Group
1 received 1 g ginger orally and 2 ml sterile water as i.v. pla-
cebo, and group 2 received 1 g lactulose as orally placebo and
10 mg of metoclopramide as i.v. injection. One gram orally
placebo and 2 ml i.v. placebo were given to group 3. Ginger
or placebo capsules were administrated 1.5 h before surgery [23].
In another study by Nanthakomon and Pongrojpaw, ginger
was an effective antiemetic agent for the prevention of
PONV. Participants randomly received 1 g powdered ginger
(500 mg per capsule) or 1 g placebo (500 mg lactulose per
capsule) 1 h before surgery [24].
Nale et al. investigated the effect of ginger on the preven-
tion of PONV in comparison with other antiemetic medica-
tions. They also recorded cost and side effects of the
medications. Participants randomly assigned to receive one
of the following six interventions: ginger 250 mg (group 1),
metoclopramide 10 mg (group 2), prochlorperazine 5 mg
(group 3), promethazine 20 mg (group 4), ondansetron
4 mg (group 5) or placebo (group 6) 1 h before surgical
procedure and at 8 h intervals for 24 h. They concluded
that ginger was a very effective intervention for the prevention
of PONV and the severity and incidence of N/V were lowest
in the ginger group than the other groups. Ginger was the
most cost-effective intervention with negligible adverse effects
compared with other drugs [25]. A meta-analysis by
Chaiyakunapruk et al. concluded that ginger is an effective
antiemetic to prevent PONV. Ginger can be used as at least
an add-on therapy to antiemetic regimen for controlling
PONV due to its availability, being inexpensive and desirable
safety profile [26].
In the present study, frequency of both N/V episodes
significantly decreased in the ginger group, but ginger was
more efficacious against vomiting compared with nausea.
This concept that antiemetics are more efficacious against
vomiting than nausea was reviewed recently by Andrews and
Sanger [27].
ART-induced gastrointestinal adverse reactions including
nausea, vomiting and dyspepsia are the most frequently
reported side effects of ART regimens [28]. Gastrointestinal
intolerance was the main cause of lopinavir/ritonavir therapy
modification or interruption, whereas it was less commonly
associated with efavirenz discontinuations [29]. The incidence
of gastrointestinal adverse reactions was higher in patients
treated with nelfinavir compared with nevirapine [30]. Also,
these reactions were the main cause of saquinavir therapy mod-
ification. However, no patient on atazanavir/ritonavir discon-
tinued treatment due to GI intolerance [31,32]. Gastrointestinal
toxicity was also reported with didanosine. Zidovudine and
F. Dabaghzadeh et al.
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didanosine showed higher rates of nausea, constipation and
fatigue compared with stavudine and lamivudine [33].
This study is the first to evaluate the antiemetic effect of
ginger on ART-induced N/V. In our study, ginger was an
effective intervention to prevent antiretroviral regimen-
induced N/V. Patients tolerated ginger well, and no consider-
able adverse effects were detected. The study was limited by its
small sample size. Moreover, the duration of patient follow-
up may not be sufficient as gastrointestinal adverse effects of
ART may occur beyond 2 weeks of therapy. Patients were fol-
lowed daily through phone during the study period. This type
of follow-up may affect the accuracy of results. VAS was used
for the assessment of the patients’ severity of nausea. Although
the scale was always being used in many studies and was
validated in this trial, the patients may not have adhered to
the scale during the follow-up period. Further randomized
clinical trials must be conducted to confirm the efficacy of
ginger in the prevention of ART-induced N/V. More studies
are required to determine the best dose and time of ginger
administration in the prevention of ART-induced N/V.
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